Intervention Protocol

Allopurinol for chronic gout

  1. Michelle Catton1,*,
  2. Naomi Schlesinger2,
  3. Xiaohong Zhou3,
  4. Ralph Schumacher4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD006077

Database Title

Additional Information

How to Cite

Catton M, Schlesinger N, Zhou X, Schumacher R. Allopurinol for chronic gout (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006077. DOI: 10.1002/14651858.CD006077.

Author Information

  1. 1

    Ottawa, Ontario, Canada

  2. 2

    UMDNJ - Robert Wood Johnson Medical School, Clinical Rheumatology, New Brunswick, NJ, USA

  3. 3

    University of Ottawa, Institute of Population Health, Ottawa, Canada

  4. 4

    Hospital of the University of Pennsylvania, Dept of Rheumatology, Philadelphia, Pennsylvania, USA

*Michelle Catton, 904-2035 Othello Ave., Ottawa, Ontario, K1G 3P6, Canada. mcatt077@uottawa.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (111K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1) To assess the efficacy and adverse effects of allopurinol versus placebo in suppressing gouty flares.

2) To assess the efficacy and adverse effects of allopurinol vs. other pharmacological agents in suppressing gouty flares.

3) To assess the efficacy and adverse effects of various regimens of allopurinol treatment in the suppression of gouty flares.

View Full Article (HTML) Full (111K)